Camillo Porta

Camillo Porta

Auto-generated profile, based on publicly available information

Camillo Porta

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari and University of Bari "A. Moro," Bari, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJosep M. Llovet
Josep M. Llovet
SRSergio Ricci
Sergio Ricci
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
PHPhilip Hilgard
Philip Hilgard
EGEdward Gane
Edward Gane
JBJordi Bruix
Jordi Bruix
No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand–foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

1 August 2008 in The Lancet
Verified
Journal Article
Closed access
RMRobert Motzer
Robert Motzer
BEBernard Escudier
Bernard Escudier
SOStéphane Oudard
Stéphane Oudard
Thomas HutsonThomas Hutson
Thomas Hutson
CPCamillo Porta
Camillo Porta
RGRECORD-1 Study Group
RECORD-1 Study Group

14 April 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CPCamillo Porta
Camillo Porta
CPChiara Paglino
Chiara Paglino
AMAlessandra Mosca
Alessandra Mosca
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

14 June 2010 in Cancer
Verified
Journal Article
Open access
PDF file
RMRobert Motzer
Robert Motzer
BEBernard Escudier
Bernard Escudier
SOStephane Oudard
Stephane Oudard
Thomas HutsonThomas Hutson
Thomas Hutson
CPCamillo Porta
Camillo Porta
FGfor the RECORD‐1 Study Group
for the RECORD‐1 Study Group
BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor–tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported.METHODS: Patients with mRCC (N = 416) were randomized (2:1) to everolimus 10 mg/d (n = 277) or placebo (n = 139) plus best supportive care. Progression‐free survival (PFS) and safety were assessed to the end of double‐blind treatment. Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses. A rank‐preserving structural failure time model estimated the effect on OS, correcting for crossover from placebo to everolimus.RESULTS: The median PFS was 4.9 months (everolimus) versus 1.9 months (placebo) (hazard ratio [HR], 0.33; P < .001) by independent central review and 5.5 months (everolimus) versus 1.9 months (placebo) (HR, 0.32; P < .001) by investigators. Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%). The median OS was 14.8 months (everolimus) versus 14.4 months (placebo) (HR, 0.87; P = .162), with 80% of patients in the placebo arm crossed over to everolimus. By the rank‐preserving structural failure time model, the survival corrected for crossover was 1.9‐fold longer (95% confidence interval, 0.5‐8.5) with everolimus compared with placebo only. Independent prognostic factors for shorter OS in the study included low performance status, high corrected calcium, low hemoglobin, and prior sunitinib (P < .01).CONCLUSIONS: These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib. Cancer 2010. © 2010 American Cancer Society.

1 October 2012 in Journal of Hepatology
Verified
Journal Article
Open access
JBJordi Bruix
Jordi Bruix
JRJean-Luc Raoul
Jean-Luc Raoul
MSMorris Sherman
Morris Sherman
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
LBLuigi Bolondi
Luigi Bolondi
JLJosep M. Llovet
Josep M. Llovet
The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety of sorafenib. Five subgroup domains were assessed: disease etiology, tumor burden, performance status, tumor stage, and prior therapy. Overall survival (OS), time to progression (TTP), disease control rate (DCR), and safety were assessed for subgroups within each domain. Subgroup analyses showed that sorafenib consistently improved median OS compared with placebo, as reflected by hazard ratios (HRs) of 0.50-0.85, similar to the complete cohort (HR=0.69). Sorafenib also consistently improved median TTP (HR, 0.40-0.64), except in HBV-positive patients (HR, 1.03), and DCR. Results are limited by small patient numbers in some subsets. The most common grade 3/4 adverse events included diarrhea, hand-foot skin reaction, and fatigue; the incidence of which did not differ appreciably among subgroups. These exploratory subgroup analyses showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage, and prior therapy.

1 August 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
MGMartin E Gore
Martin E Gore
CSCezary Szczylik
Cezary Szczylik
CPCamillo Porta
Camillo Porta
SBSergio Bracarda
Sergio Bracarda
GBGeorg A Bjarnason
Georg A Bjarnason
RBRonald Bukowski
Ronald Bukowski